Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	histone H3K4 monomethyltransferase activity	KMT2A KMT2C	1.09e-04	8	40	2	GO:0140945
GeneOntologyMolecularFunction	histone H3K4 trimethyltransferase activity	KMT2A KMT2C	1.74e-04	10	40	2	GO:0140999
Domain	AT_hook	PRR12 KMT2A KMT2C	4.27e-06	16	38	3	PF02178
Domain	AT_hook	PRR12 KMT2A KMT2C	2.20e-05	27	38	3	SM00384
Domain	AT_hook_DNA-bd_motif	PRR12 KMT2A KMT2C	2.20e-05	27	38	3	IPR017956
Domain	FYrich_C	KMT2A KMT2C	4.02e-05	5	38	2	IPR003889
Domain	FYrich_N	KMT2A KMT2C	4.02e-05	5	38	2	IPR003888
Domain	FYRC	KMT2A KMT2C	4.02e-05	5	38	2	SM00542
Domain	FYRN	KMT2A KMT2C	4.02e-05	5	38	2	SM00541
Domain	FYRN	KMT2A KMT2C	4.02e-05	5	38	2	PF05964
Domain	FYRC	KMT2A KMT2C	4.02e-05	5	38	2	PF05965
Domain	FYRC	KMT2A KMT2C	4.02e-05	5	38	2	PS51543
Domain	FYRN	KMT2A KMT2C	4.02e-05	5	38	2	PS51542
Domain	EGF_2	EPHB2 DNER ADGRE2 MUC4 ATRAID	1.90e-04	265	38	5	PS01186
Domain	Post-SET_dom	KMT2A KMT2C	4.75e-04	16	38	2	IPR003616
Domain	PostSET	KMT2A KMT2C	4.75e-04	16	38	2	SM00508
Domain	POST_SET	KMT2A KMT2C	4.75e-04	16	38	2	PS50868
Domain	SAM	EPHB2 STIM1 SAMD4B	7.57e-04	88	38	3	SM00454
Domain	EPHD	KMT2A KMT2C	9.08e-04	22	38	2	PS51805
Domain	SAM_DOMAIN	EPHB2 STIM1 SAMD4B	9.45e-04	95	38	3	PS50105
Domain	SAM	EPHB2 STIM1 SAMD4B	1.00e-03	97	38	3	IPR001660
Domain	FERM_C	FRMD4A FRMPD2	1.27e-03	26	38	2	PF09380
Domain	EGF_3	DNER ADGRE2 MUC4 ATRAID	1.29e-03	235	38	4	PS50026
Domain	EGF	DNER ADGRE2 MUC4 ATRAID	1.29e-03	235	38	4	SM00181
Domain	-	EPHB2 STIM1 SAMD4B	1.30e-03	106	38	3	1.10.150.50
Domain	FERM_C	FRMD4A FRMPD2	1.37e-03	27	38	2	SM01196
Domain	FERM_PH-like_C	FRMD4A FRMPD2	1.37e-03	27	38	2	IPR018980
Domain	EGF-like_dom	DNER ADGRE2 MUC4 ATRAID	1.59e-03	249	38	4	IPR000742
Domain	SAM/pointed	EPHB2 STIM1 SAMD4B	1.72e-03	117	38	3	IPR013761
Domain	EGF_1	DNER ADGRE2 MUC4 ATRAID	1.74e-03	255	38	4	PS00022
Domain	HMGI/Y_DNA-bd_CS	PRR12 KMT2C	1.81e-03	31	38	2	IPR000637
Domain	EGF-like_CS	DNER ADGRE2 MUC4 ATRAID	1.89e-03	261	38	4	IPR013032
Domain	FERM_N	FRMD4A FRMPD2	2.05e-03	33	38	2	IPR018979
Domain	FERM_N	FRMD4A FRMPD2	2.05e-03	33	38	2	PF09379
Domain	-	EPHB2 HLA-C KIR3DS1 SIGLEC15 CD300C CD276	2.05e-03	663	38	6	2.60.40.10
Domain	Ig-like_fold	EPHB2 HLA-C KIR3DS1 SIGLEC15 CD300C CD276	2.81e-03	706	38	6	IPR013783
Domain	SET	KMT2A KMT2C	3.14e-03	41	38	2	PF00856
Domain	Ig-like_dom	HLA-C KIR3DS1 SIGLEC15 CD300C CD276	3.35e-03	503	38	5	IPR007110
Domain	Growth_fac_rcpt_	EPHB2 DNER ADGRE2	3.89e-03	156	38	3	IPR009030
Domain	SET	KMT2A KMT2C	3.94e-03	46	38	2	SM00317
Domain	FERM_M	FRMD4A FRMPD2	3.94e-03	46	38	2	PF00373
Domain	FERM_central	FRMD4A FRMPD2	4.46e-03	49	38	2	IPR019748
Domain	FERM_domain	FRMD4A FRMPD2	4.46e-03	49	38	2	IPR000299
Domain	-	FRMD4A FRMPD2	4.46e-03	49	38	2	1.20.80.10
Domain	SET_dom	KMT2A KMT2C	4.64e-03	50	38	2	IPR001214
Domain	FERM_1	FRMD4A FRMPD2	4.64e-03	50	38	2	PS00660
Domain	FERM_2	FRMD4A FRMPD2	4.64e-03	50	38	2	PS00661
Domain	Band_41_domain	FRMD4A FRMPD2	4.64e-03	50	38	2	IPR019749
Domain	B41	FRMD4A FRMPD2	4.64e-03	50	38	2	SM00295
Domain	FERM/acyl-CoA-bd_prot_3-hlx	FRMD4A FRMPD2	4.64e-03	50	38	2	IPR014352
Domain	SET	KMT2A KMT2C	4.64e-03	50	38	2	PS50280
Domain	FERM_3	FRMD4A FRMPD2	4.64e-03	50	38	2	PS50057
Domain	zf-RING_2	RNF223 RNF115	5.01e-03	52	38	2	PF13639
Domain	HMG_box	KMT2C TCF7	5.20e-03	53	38	2	PF00505
Domain	HMG	KMT2C TCF7	5.40e-03	54	38	2	SM00398
Domain	IGc1	HLA-C CD276	5.79e-03	56	38	2	SM00407
Domain	V-set	SIGLEC15 CD300C CD276	6.16e-03	184	38	3	PF07686
Domain	Ig_C1-set	HLA-C CD276	6.20e-03	58	38	2	IPR003597
Domain	Ig_V-set	SIGLEC15 CD300C CD276	7.64e-03	199	38	3	IPR013106
Domain	HMG_box_dom	KMT2C TCF7	7.73e-03	65	38	2	IPR009071
Domain	SAM_1	EPHB2 SAMD4B	8.44e-03	68	38	2	PF00536
Pubmed	NUP98-MLL fusion in human acute myeloblastic leukemia.	NUP98 KMT2A	1.49e-06	2	43	2	20558618
Pubmed	Immunocytochemistry for MUC4 and MUC16 is a useful adjunct in the diagnosis of pancreatic adenocarcinoma on fine-needle aspiration cytology.	MUC16 MUC4	1.49e-06	2	43	2	23544943
Pubmed	Microbial products alter the expression of membrane-associated mucin and antimicrobial peptides in a three-dimensional human endocervical epithelial cell model.	MUC16 MUC4	4.48e-06	3	43	2	23053434
Pubmed	NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis.	NUP98 KMT2A	4.48e-06	3	43	2	27889185
Pubmed	MLL is essential for NUP98-HOXA9-induced leukemia.	NUP98 KMT2A	4.48e-06	3	43	2	28210005
Pubmed	Integrative analysis of the cancer genome atlas and cancer cell lines encyclopedia large-scale genomic databases: MUC4/MUC16/MUC20 signature is associated with poor survival in human carcinomas.	MUC16 MUC4	4.48e-06	3	43	2	30236127
Pubmed	Regulation of membrane-associated mucins in the human corneal epithelial cells by dexamethasone.	MUC16 MUC4	4.48e-06	3	43	2	17592322
Pubmed	Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription.	KMT2A KMT2C	4.48e-06	3	43	2	23932714
Pubmed	The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.	NUP98 KMT2A	4.48e-06	3	43	2	34582559
Pubmed	miR-99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancer.	E2F2 ADGRE2	4.48e-06	3	43	2	29072692
Pubmed	Recurrent YAP1 and KMT2A Gene Rearrangements in a Subset of MUC4-negative Sclerosing Epithelioid Fibrosarcoma.	KMT2A MUC4	4.48e-06	3	43	2	31592798
Pubmed	Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection.	MUC16 MUC4	4.48e-06	3	43	2	35879412
Pubmed	Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling).	MUC16 MUC4	4.48e-06	3	43	2	27483328
Pubmed	MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer.	MUC16 MUC4	4.48e-06	3	43	2	24204560
Pubmed	Polymorphisms of KIRs gene and HLA-C alleles in patients with ankylosing spondylitis: possible association with susceptibility to the disease.	HLA-C KIR3DS1	4.48e-06	3	43	2	18297378
Pubmed	Expression of the transmembrane mucins, MUC1, MUC4 and MUC16, in normal endometrium and in endometriosis.	MUC16 MUC4	4.48e-06	3	43	2	24939955
Pubmed	Association of killer cell immunoglobulin-like receptor genotypes with susceptibility to endometriosis.	HLA-C KIR3DS1	8.94e-06	4	43	2	17997746
Pubmed	A subset of mixed lineage leukemia proteins has plant homeodomain (PHD)-mediated E3 ligase activity.	KMT2A KMT2C	8.94e-06	4	43	2	23129768
Pubmed	Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II.	KMT2A KMT2C	8.94e-06	4	43	2	19703992
Pubmed	The MLL3/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers.	KMT2A KMT2C	8.94e-06	4	43	2	24081332
Pubmed	TRPV4 activation in human corneal epithelial cells promotes membrane mucin production.	MUC16 MUC4	8.94e-06	4	43	2	39024979
Pubmed	The role of STIM and ORAI proteins in phagocytic immune cells.	STIM1 GNAS	1.49e-05	5	43	2	26764049
Pubmed	Genetic associations of killer immunoglobulin like receptors and class I human leukocyte antigens on childhood acute lymphoblastic leukemia among north Indians.	HLA-C KIR3DS1	1.49e-05	5	43	2	26472014
Pubmed	The Chromatin Regulator Mll1 Supports T Follicular Helper Cell Differentiation by Controlling Expression of Bcl6, LEF-1, and TCF-1.	KMT2A TCF7	1.49e-05	5	43	2	37074193
Pubmed	Killer cell immunoglobulin-like receptor genotypes in Japanese patients with type 1 diabetes.	HLA-C KIR3DS1	1.49e-05	5	43	2	17990989
Pubmed	Dynamic Protein Interactions of the Polycomb Repressive Complex 2 during Differentiation of Pluripotent Cells.	NUP98 KMT2A KMT2C MUC4 CDK13 TASOR2	2.33e-05	469	43	6	27634302
Pubmed	Identification of NPM-ALK interacting proteins by tandem mass spectrometry.	NUP98 EPHB2 CDK13	2.75e-05	47	43	3	14968112
Pubmed	Clustered PHD domains in KMT2/MLL proteins are attracted by H3K4me3 and H3 acetylation-rich active promoters and enhancers.	KMT2A KMT2C	3.12e-05	7	43	2	36598580
Pubmed	Unique Role of the WD-40 Repeat Protein 5 (WDR5) Subunit within the Mixed Lineage Leukemia 3 (MLL3) Histone Methyltransferase Complex.	KMT2A KMT2C	3.12e-05	7	43	2	26324722
Pubmed	HLA-F and MHC-I Open Conformers Bind Natural Killer Cell Ig-Like Receptor KIR3DS1.	HLA-C KIR3DS1	4.16e-05	8	43	2	27649529
Pubmed	Skirting the pitfalls: a clear-cut nomenclature for H3K4 methyltransferases.	KMT2A KMT2C	4.16e-05	8	43	2	23130995
Pubmed	The plasticity of WDR5 peptide-binding cleft enables the binding of the SET1 family of histone methyltransferases.	KMT2A KMT2C	4.16e-05	8	43	2	22266653
Pubmed	Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark.	KMT2A E2F2	4.16e-05	8	43	2	20855524
Pubmed	Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases.	KMT2A KMT2C	5.35e-05	9	43	2	22665483
Pubmed	Combination of KIR and HLA gene variants augments the risk of developing birdshot chorioretinopathy in HLA-A*29-positive individuals.	HLA-C KIR3DS1	5.35e-05	9	43	2	18340360
Pubmed	Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression.	KMT2A E2F2	5.35e-05	9	43	2	16951254
Pubmed	Association of killer cell immunoglobulin-like receptors with primary Sjogren's syndrome.	HLA-C KIR3DS1	9.78e-05	12	43	2	19181658
Pubmed	Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.	KMT2A KMT2C	9.78e-05	12	43	2	27563068
Pubmed	[Relationship between CMV reactivation and KIR haplotype/HLA-Cw genotype in patients after unrelated-donor hematopoietic stem cell transplantation.].	HLA-C KIR3DS1	9.78e-05	12	43	2	20137308
Pubmed	Distribution of killer cell immunoglobulin-like receptors (KIR) and their HLA-C ligands in two Iranian populations.	HLA-C KIR3DS1	9.78e-05	12	43	2	19936734
Pubmed	Dynamic patterns of histone H3 lysine 4 methyltransferases and demethylases during mouse preimplantation development.	KMT2A KMT2C	1.15e-04	13	43	2	24619213
Pubmed	KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.	HLA-C KIR3DS1	1.15e-04	13	43	2	19934297
Pubmed	Different KIRs confer susceptibility and protection to adults with latent autoimmune diabetes in Latvian and Asian Indian populations.	HLA-C KIR3DS1	1.15e-04	13	43	2	19120281
Pubmed	Enzymatic nucleosome acetylation selectively affects activity of histone methyltransferases in vitro.	KMT2A KMT2C	1.55e-04	15	43	2	35907431
Pubmed	Killer cell immunoglobulin-like receptors in HLA-B27-associated acute anterior uveitis, with and without axial spondyloarthropathy.	HLA-C KIR3DS1	1.55e-04	15	43	2	19850842
Pubmed	Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity.	KMT2A HLA-C	1.55e-04	15	43	2	38413714
Pubmed	Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia.	HLA-C KIR3DS1	1.55e-04	15	43	2	19493232
Pubmed	[Killer cell immunoglobin-like receptor and its ligand gene polymorphisms in Hunan Han patients with type 1 diabetes].	HLA-C KIR3DS1	1.55e-04	15	43	2	20356536
Pubmed	Inhibitory KIR and specific HLA-C gene combinations confer susceptibility to or protection against chronic hepatitis B.	HLA-C KIR3DS1	1.55e-04	15	43	2	20643584
Pubmed	Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.	HLA-C KIR3DS1	1.55e-04	15	43	2	19326408
Pubmed	SET1 and p300 act synergistically, through coupled histone modifications, in transcriptional activation by p53.	KMT2A KMT2C	1.77e-04	16	43	2	23870121
Pubmed	Polymorphisms of KIR gene and HLA-C alleles: possible association with susceptibility to HLA-B27-positive patients with ankylosing spondylitis.	HLA-C KIR3DS1	1.77e-04	16	43	2	20652381
Pubmed	No association of KIR genes with Behcet's disease.	HLA-C KIR3DS1	1.77e-04	16	43	2	17868255
Pubmed	A study of the killer cell immunoglobulin-like receptor gene KIR2DS1 in a Caucasoid Brazilian population with psoriasis vulgaris.	HLA-C KIR3DS1	1.77e-04	16	43	2	18643961
Pubmed	HLA-DQA1*0505 sharing and killer immunoglobulin-like receptors in sub fertile couples: report from the 15th International Histocompatibility Workshop.	HLA-C KIR3DS1	1.77e-04	16	43	2	20210919
Pubmed	Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation.	HLA-C KIR3DS1	2.01e-04	17	43	2	19032228
Pubmed	The beneficial impact of missing KIR ligands and absence of donor KIR2DS3 gene on outcome following unrelated hematopoietic SCT for myeloid leukemia in the Chinese population.	HLA-C KIR3DS1	2.01e-04	17	43	2	20173784
Pubmed	The role of killer immunoglobulin-like receptor haplotypes on the outcome of unrelated donor haematopoietic SCT for thalassaemia.	HLA-C KIR3DS1	2.01e-04	17	43	2	20173792
Pubmed	Role of killer cell immunoglobulin-like receptor gene content and human leukocyte antigen-C group in susceptibility to human T-lymphotropic virus 1-associated myelopathy/tropical spastic paraparesis in Peru.	HLA-C KIR3DS1	2.01e-04	17	43	2	20483367
Pubmed	[Effects of killer immunoglobulin-like receptor and human leukocyte antigen class I ligand on the prognosis of related donor hematopoietic stem cell transplantation].	HLA-C KIR3DS1	2.01e-04	17	43	2	19968064
Pubmed	Isolation and fine mapping of 16 novel human zinc finger-encoding cDNAs identify putative candidate genes for developmental and malignant disorders.	ZNF135 ZKSCAN1	2.01e-04	17	43	2	7557990
Pubmed	KIR genes and KIR ligands affect occurrence of acute GVHD after unrelated, 12/12 HLA matched, hematopoietic stem cell transplantation.	HLA-C KIR3DS1	2.01e-04	17	43	2	19169284
Pubmed	Mucin gene expression in human laryngeal epithelia: effect of laryngopharyngeal reflux.	MUC16 MUC4	2.26e-04	18	43	2	18834073
Pubmed	Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis.	HLA-C KIR3DS1	2.26e-04	18	43	2	19630074
Pubmed	Influence of HLA class I and HLA-KIR compound genotypes on HIV-2 infection and markers of disease progression in a Manjako community in West Africa.	HLA-C KIR3DS1	2.26e-04	18	43	2	20519398
Pubmed	Combination of KIR 2DL2 and HLA-C1 (Asn 80) confers susceptibility to type 1 diabetes in Latvians.	HLA-C KIR3DS1	2.26e-04	18	43	2	19046302
Pubmed	Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection.	HLA-C KIR3DS1	2.26e-04	18	43	2	19846535
Pubmed	Association of killer cell immunoglobulin-like receptors and human leukocyte antigen-C genotypes in South Brazilian with type 1 diabetes.	HLA-C KIR3DS1	2.26e-04	18	43	2	20580654
Pubmed	Distribution of killer cell immunoglobulin-like receptor genes in the mestizo population from Venezuela.	HLA-C KIR3DS1	2.26e-04	18	43	2	20210918
Pubmed	KIR and HLA gene combinations in Vogt-Koyanagi-Harada disease.	HLA-C KIR3DS1	2.52e-04	19	43	2	18571006
Pubmed	Association between killer-cell immunoglobulin-like receptor genotypes and leprosy in Brazil.	HLA-C KIR3DS1	2.52e-04	19	43	2	18778326
Pubmed	Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors.	HLA-C KIR3DS1	2.52e-04	19	43	2	20600442
Pubmed	Killer cell immunoglobulin-like receptor gene diversity in a Southern Brazilian population from the state of Paraná.	HLA-C KIR3DS1	2.52e-04	19	43	2	18848853
Pubmed	Compound KIR-HLA genotype analyses in the Iranian population by a novel PCR-SSP assay.	HLA-C KIR3DS1	2.80e-04	20	43	2	20193031
Pubmed	Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.	KMT2C HAX1	2.80e-04	20	43	2	29785026
Pubmed	HLA and KIR frequencies in Sicilian Centenarians.	HLA-C KIR3DS1	2.80e-04	20	43	2	20426625
Pubmed	Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis.	HLA-C KIR3DS1	3.09e-04	21	43	2	19861144
Pubmed	Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition.	KMT2A KMT2C	3.09e-04	21	43	2	27626377
Pubmed	Structural basis for activity regulation of MLL family methyltransferases.	KMT2A KMT2C	3.40e-04	22	43	2	26886794
Pubmed	Distribution of KIR genes in the population of unrelated individuals homozygous for ancestral haplotype AH8.1 (HLA-A1B8DR3).	HLA-C KIR3DS1	3.40e-04	22	43	2	20492596
Pubmed	Chromosomal localization of genes encoding guanine nucleotide-binding protein subunits in mouse and human.	GNAS HLA-C	4.05e-04	24	43	2	2902634
Pubmed	An improved smaller biotin ligase for BioID proximity labeling.	NUP98 STIM1 AHNAK2	4.80e-04	123	43	3	26912792
Pubmed	Rebalancing gene haploinsufficiency in vivo by targeting chromatin.	KMT2A KMT2C	5.53e-04	28	43	2	27256596
Pubmed	Novel interactors and a role for supervillin in early cytokinesis.	KMT2A HAX1	5.53e-04	28	43	2	20309963
Pubmed	Immunogenetic characteristics of patients with autoimmune gastritis.	HLA-C KIR3DS1	5.93e-04	29	43	2	20082482
Pubmed	Role of human leukocyte antigen, killer-cell immunoglobulin-like receptors, and cytokine gene polymorphisms in leptospirosis.	HLA-C KIR3DS1	8.66e-04	35	43	2	19683555
Pubmed	Interaction network of human early embryonic transcription factors.	NUP98 PRR12 KMT2A KMT2C	9.23e-04	351	43	4	38297188
Pubmed	Phase-separated nuclear bodies of nucleoporin fusions promote condensation of MLL1/CRM1 and rearrangement of 3D genome structure.	NUP98 KMT2A	1.13e-03	40	43	2	37516964
GeneFamily	Sterile alpha motif domain containing	EPHB2 STIM1 SAMD4B	4.11e-04	88	30	3	760
GeneFamily	CD molecules\|Mucins	MUC16 MUC4	5.48e-04	21	30	2	648
GeneFamily	Zinc fingers C2H2-type\|Lysine methyltransferases\|PR/SET domain family	KMT2A KMT2C	1.44e-03	34	30	2	487
GeneFamily	Adenosine receptors\|V-set domain containing	SIGLEC15 CD300C CD276	2.44e-03	163	30	3	590
GeneFamily	Ankyrin repeat domain containing\|FERM domain containing	FRMD4A FRMPD2	3.10e-03	50	30	2	1293
GeneFamily	ADAM metallopeptidase domain containing\|CD molecules	ADGRE2 GYPC CD300C CD276	3.89e-03	394	30	4	471
GeneFamily	PHD finger proteins	KMT2A KMT2C	9.74e-03	90	30	2	88
ToppCell	Healthy/Control-CD8+_Tem\|World / Disease group and Cell class	USP36 TCF7 HLA-C RNF115 GYPC	1.11e-06	196	42	5	a6dc92476156a695e15373ea57dc04e30014ac55
ToppCell	wk_15-18-Epithelial-Proximal_epithelial-Proximal_secretory_3\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	MUC16 ATP13A4 MUC4 AHNAK2	2.26e-05	176	42	4	8d9d0fb46c418b2067be58aec822e8c2b1561461
ToppCell	BAL-Severe-Epithelial-Epithelial-undefined_Epi-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	MUC16 RNF223 SLC5A12 MUC4	2.36e-05	178	42	4	9a3ef66814dfca7b37024e7f79e86ea8c72ae10f
ToppCell	BAL-Severe-Epithelial-Epithelial-undefined_Epi\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	MUC16 RNF223 SLC5A12 MUC4	2.36e-05	178	42	4	19b5432aa1d7f616d58a106543c18cf2d7ca840c
ToppCell	BAL-Severe-Epithelial-Epithelial-undefined_Epi-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	MUC16 RNF223 SLC5A12 MUC4	2.36e-05	178	42	4	b413a634283550fa224db7d0d05956e3f64694a1
ToppCell	BAL-Severe-Epithelial-Epithelial-undefined_Epi\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	MUC16 RNF223 SLC5A12 MUC4	2.36e-05	178	42	4	49a2271718637522f74334068d252963ee13b1ce
ToppCell	Ciliated_cells-A-Myositis-ILD_01\|World / lung cells shred on cell class, cell subclass, sample id	DNER MUC16 MAP1A MUC4	2.68e-05	184	42	4	07c5a9633ccdcd18771e3230d6198a55c400afa6
ToppCell	Ciliated_cells-B-Donor_07\|World / lung cells shred on cell class, cell subclass, sample id	MAP1A MUC4 FRMPD2 AHNAK2	2.92e-05	188	42	4	606907c865bd2f11bb6474932716550f7723d858
ToppCell	PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51\|PBMC_fresh-frozen / Compartment, severity and other cell annotations on 10x 3' data (130k)	PNRC1 TCF7 GNAS HLA-C	2.98e-05	189	42	4	0e8d1be3c406d1a393e18faccfe89116a8f82bcf
ToppCell	metastatic_Brain-T/NK_cells-CD4+_Th\|metastatic_Brain / Location, Cell class and cell subclass	PNRC1 TCF7 HLA-C GYPC	2.98e-05	189	42	4	a2b00fbe7b7b15db3fce88a56cbac0ef2917332c
ToppCell	Control-Epithelial-Ciliated_cells\|Control / Condition, Lineage and Cell class	MUC16 MUC4 FRMPD2 AHNAK2	3.10e-05	191	42	4	ea1d2c6838119b7019e9a2ff71d6212262b51b57
ToppCell	Control-Epithelial\|Control / Condition, Lineage and Cell class	MUC16 MUC4 FRMPD2 AHNAK2	3.10e-05	191	42	4	6228302febdb3dffe37dece7062d27ac9ccc6d4b
ToppCell	CD8+_Memory_T_cell-CV-0\|CD8+_Memory_T_cell / cell class, Virus stimulation and cluster	PNRC1 TCF7 ADGRE2 HLA-C	3.23e-05	193	42	4	995781d87a919c0380750878bafe584342bb83ad
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c01-LEF1\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	PNRC1 TCF7 GNAS GYPC	3.23e-05	193	42	4	4e78ddc96d8e403a21c4a303b1f26512d2ac91e8
ToppCell	10x5'-Liver-Lymphocytic_T_CD4/8-lo-Tgd_CRTAM\|Liver / Manually curated celltypes from each tissue	KMT2A PNRC1 GNAS HLA-C	3.37e-05	195	42	4	972b09697b7b66fb8a27dfc0c0b05a844121f055
ToppCell	10x5'-Liver-Lymphocytic_T_CD4/8-lo\|Liver / Manually curated celltypes from each tissue	KMT2A PNRC1 GNAS HLA-C	3.37e-05	195	42	4	c29c4ae95a756e3ced0f0747bbfe343590e5b8ab
ToppCell	Secretory\|World / shred by cell class for bronchial biopsy	MUC16 GNAS HLA-C MUC4	3.37e-05	195	42	4	52f8281fe0df67cec3faa780a23ed6343ed5a6ba
ToppCell	Healthy_donor-CD8+_Tem\|World / disease group, cell group and cell class (v2)	TCF7 HLA-C RNF115 GYPC	3.43e-05	196	42	4	b04684d319d0c462862677d0f956a389bffef535
ToppCell	10x5'-Liver-Lymphocytic_T_CD8-Trm/em_CD8\|Liver / Manually curated celltypes from each tissue	KMT2A PNRC1 GNAS HLA-C	3.43e-05	196	42	4	91c85ea202508185142ef67af6d27d0932567ca0
ToppCell	10x_3'_v3\|World / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	PNRC1 GNAS HLA-C GYPC	3.57e-05	198	42	4	aabb8e9b162ae4cb26ea860c99decdbb51e379e1
ToppCell	Monocytes-Phagocytic_CD16+_macrophages\|World / Immune cells in Kidney/Urine in Lupus Nephritis	EPHB2 ADGRE2 CD300C CD276	3.57e-05	198	42	4	09009cc966bf1503c3b15dfa079a6c5f6ad1f507
ToppCell	mild-CD4+_T_naive\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	KMT2A PNRC1 TCF7 GYPC	3.64e-05	199	42	4	3e4baaf4ee23f257d821194468102c00a8ad2f21
ToppCell	5'-Adult-LymphNode\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PNRC1 TCF7 HLA-C GYPC	3.64e-05	199	42	4	098ff8badf67c382d8ddfa6b33f5035a26f2fd5f
ToppCell	severe-CD8+_T_naive\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	PNRC1 TCF7 GNAS GYPC	3.72e-05	200	42	4	61c7c08460856c188e62edf1fa62855578146fc8
ToppCell	5'-Adult-LymphNode-Hematopoietic-T_cells\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PNRC1 TCF7 HLA-C GYPC	3.72e-05	200	42	4	cf4d184ff07862fabb182dabf09b2c9aac491409
ToppCell	severe-CD8+_Tem\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	PNRC1 GNAS HLA-C GYPC	3.72e-05	200	42	4	6aa77955017d073a96324e4db6b9950a2ec46cf8
ToppCell	COVID-19\|World / Disease, condition lineage and cell class	KMT2A KMT2C GNAS CDK13	3.72e-05	200	42	4	7dec470c379cd89f05a0f37c8628b21f136e52f0
ToppCell	5'-Adult-LymphNode-Hematopoietic\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PNRC1 TCF7 HLA-C GYPC	3.72e-05	200	42	4	7dee3da190c78cb72970123eb8768618584ebeea
ToppCell	severe-CD4+_Tcm\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	PNRC1 TCF7 GNAS GYPC	3.72e-05	200	42	4	e83558090a079dd9e40e0d3b5d9917fbd2695ec4
ToppCell	severe-CD4+_T_naive\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	PNRC1 TCF7 GNAS GYPC	3.72e-05	200	42	4	f74bdabadca8ad6dae1b6e6812c66325aac50db0
ToppCell	Control-Epithelial_alveolar-Mes-Like\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ATP13A4 SHF ATRAID	1.78e-04	116	42	3	df7609503782d8d7e4f31ed2a626916e5474d5bc
ToppCell	NS-moderate-d_07-13-Epithelial-unknown_epithelial\|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	MUC16 RNF223 MUC4	2.49e-04	130	42	3	1491e8975520e99c527a5b5bee64875d124f7bf4
ToppCell	ILEUM-non-inflamed-(3)_MNP-(3)_moDC\|(3)_MNP / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	FRMD4A GNAS SAMD4B	2.78e-04	135	42	3	b7a792a7c0c22d8b703509f134115f0e394d7de0
ToppCell	pdx-Tumor_cells-T4\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	MUC16 HLA-C MUC4	3.94e-04	152	42	3	7ccc56b79c499dd48dab8e2d936edca5223b9356
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	EPHB2 MUC16 SLC5A12	4.02e-04	153	42	3	499670e716fc85ce76630fc813cec86f8419f2a1
ToppCell	15-Airway-Epithelial-Club-like_secretory\|Airway / Age, Tissue, Lineage and Cell class	MUC16 ATP13A4 MUC4	5.46e-04	170	42	3	1418031cc4b4a87a48621eb53a3c819cd713ddd0
ToppCell	droplet-Spleen-nan-18m-Myeloid-macrophage_dendritic_cell_progenitor\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	EPHB2 FRMD4A CD300C	5.55e-04	171	42	3	4e856441063e9825b6f87a1d3dd19c77dae4662c
ToppCell	metastatic_Brain-T/NK_cells-Cytotoxic_CD8+_T\|metastatic_Brain / Location, Cell class and cell subclass	TCF7 HLA-C GYPC	5.55e-04	171	42	3	d3e1cc1b70256c4d01488d6b6130bbcae99bdeec
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	EPHB2 DNER AHNAK2	5.65e-04	172	42	3	0c2d0bb767e5ce089b42ad49e8b303a103de2d5c
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Thick_Ascending_Limb_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	EPHB2 DNER AHNAK2	5.65e-04	172	42	3	eeed177a03c116e9815a8e086d24efc9643b16a4
ToppCell	Control-CD4+_T_activated\|World / Disease group and Cell class	FRMD4A PNRC1 SAMD4B	5.74e-04	173	42	3	12f8e4276b290bb388a56de4c8d8dd60415b2f63
ToppCell	5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.4\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MUC16 SHF MUC4	5.74e-04	173	42	3	176b956e71d98e8275d698b39437fc326e5fe449
ToppCell	TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-5\|TCGA-Pancreas / Sample_Type by Project: Shred V9	MUC16 MUC4 AHNAK2	5.84e-04	174	42	3	73e1ad4007d94fca25ed7c6fbe5d205d4e1b8a3b
ToppCell	wk_20-22-Epithelial-Proximal_epithelial-Proximal_secretory_3\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	MUC16 ATP13A4 MUC4	5.84e-04	174	42	3	9e5fae9ecc7c0111fc8a252e72b89dc89c0d3a7c
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c02-GPR183\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	PNRC1 TCF7 GYPC	5.94e-04	175	42	3	f456d8d958b71f7a942b718605712593d9de1bfd
ToppCell	343B-Myeloid-Macrophage-FABP4+_Macrophage\|343B / Donor, Lineage, Cell class and subclass (all cells)	FRMD4A CD300C CD276	5.94e-04	175	42	3	d3890bd0c570bb81434fdd1c5229891cefe2e462
ToppCell	CV-Mild-6\|Mild / Virus stimulation, Condition and Cluster	NUP98 USP36 SAMD4B	5.94e-04	175	42	3	c4d530dbb37942427c9cd0a1533faeb6a3a45381
ToppCell	3'-Distal_airway-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MUC16 RNF223 MUC4	5.94e-04	175	42	3	8252ddc2ca95071381f0354aefb70c4714828491
ToppCell	3'-Distal_airway-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MUC16 RNF223 MUC4	5.94e-04	175	42	3	8ccf60fc469059d7aaf4e6ce54159db2962e0060
ToppCell	COVID-19_Mild-Neu_3\|COVID-19_Mild / 5 Neutrophil clusters in COVID-19 patients	E2F2 MAP1A GYPC	6.04e-04	176	42	3	2049767fd591045cfcf5b1071d80798e52843f27
ToppCell	nucseq-Epithelial-Epithelial_Glandular\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	MUC16 MUC4 AHNAK2	6.34e-04	179	42	3	859cd8ee414ad6207c046ada2e655e49322dd01c
ToppCell	Ciliated_cells-A-Donor_07\|World / lung cells shred on cell class, cell subclass, sample id	MUC16 MAP1A MUC4	6.45e-04	180	42	3	d9be152773fe9f2160edad9246fa03c03afeafd6
ToppCell	nucseq-Epithelial-Epithelial_Glandular-Goblet\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	MUC16 MUC4 AHNAK2	6.45e-04	180	42	3	3dc80bc636bf0e6ffc9762853132a9fe59fd1f66
ToppCell	nucseq-Epithelial-Epithelial_Glandular-Goblet-Goblet\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	MUC16 MUC4 AHNAK2	6.45e-04	180	42	3	668a2d8e1d5a390309d5eb62c836f5903144bea9
ToppCell	5'-Airway_Nasal-Immune_Myeloid-Myeloid_monocytic-classical_monocyte-Classical_monocytes-Classical_monocytes_L.1.2.0.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	PNRC1 ADGRE2 CD300C	6.66e-04	182	42	3	c3eafdc11858566aa7692b2f5dbe72ac01fb769a
ToppCell	5'-Airway_Nasal-Immune_Myeloid-Myeloid_monocytic\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	PNRC1 ADGRE2 CD300C	6.76e-04	183	42	3	cff3197e9ff401362501db2317c86adc6d24b595
ToppCell	5'-Airway_Nasal-Immune_Myeloid-Myeloid_monocytic-classical_monocyte-Classical_monocytes\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	PNRC1 ADGRE2 CD300C	6.76e-04	183	42	3	f803dd2881ceaed6327e21a1a51bc3d3ccf4b5f8
ToppCell	5'-Airway_Nasal-Immune_Myeloid-Myeloid_monocytic-classical_monocyte\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	PNRC1 ADGRE2 CD300C	6.76e-04	183	42	3	4bd6883daf2dbe8c1b49b776b48d41f9890d1cb4
ToppCell	normal-na-Lymphocytic_T-T8_naive-male\|normal / PBMC cell types (v2) per disease, treatment status, and sex	TCF7 GYPC SPATA16	6.87e-04	184	42	3	4a81190b36d197736663e6177d3b76c1cb6282d6
ToppCell	5'-Adult-LargeIntestine-Hematopoietic-T_cells-SELL+_CD8_T\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PNRC1 TCF7 GYPC	6.87e-04	184	42	3	d5b8604142ae70abbfa4ea881ce55b2a3a2a46a6
ToppCell	COVID-19_Severe-RBC\|COVID-19_Severe / disease group, cell group and cell class	FRMD4A E2F2 GYPC	6.87e-04	184	42	3	bb58244194ffb5558fbe85c5f856888210dcb1e8
ToppCell	3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-bronchial_goblet_cell-Goblet_(bronchial)-Goblet_(bronchial)_L.0.4.2.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MUC16 RNF223 MUC4	6.87e-04	184	42	3	01c19a830348ab0b9c02c1546a439de70ee10f97
ToppCell	5'-Adult-LymphNode-Hematopoietic-T_cells-ILC3\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PNRC1 TCF7 GYPC	6.98e-04	185	42	3	7d6954bb04368ec62b284ba6c3021a15fbdfdee6
ToppCell	Smart-seq2-lymph_node_(Smart-seq2)-lymphocytic-T_lymphocytic\|lymph_node_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	TCF7 HLA-C GYPC	6.98e-04	185	42	3	115a74d0b9be580005d45d22d6e228801b2705e2
ToppCell	kidney_cells-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	E2F2 MUC4 AHNAK2	6.98e-04	185	42	3	4d0f3d86fab02c80093e62cb0c79c586c13c5412
ToppCell	COVID-19_Severe-RBC\|World / disease group, cell group and cell class	FRMD4A E2F2 GYPC	6.98e-04	185	42	3	96b7058b1b282134970aa9e75285760a9f94a8b5
ToppCell	NS-moderate-d_16-33-Epithelial-Ciliated\|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	DNER MAP1A FRMPD2	6.98e-04	185	42	3	5e689c2fb36ce3ac2adc8d15f67107f21cf68868
ToppCell	Ciliated_cells-B-Myositis-ILD_01\|World / lung cells shred on cell class, cell subclass, sample id	MUC16 MAP1A FRMPD2	6.98e-04	185	42	3	f012c243343e1d1956db19b34d062e9b13de2b2a
ToppCell	10x5'v1-week_12-13-Myeloid_macrophage-stroma-osteoclast\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	SIGLEC15 AHNAK2 CD276	7.09e-04	186	42	3	c9dfcf7bba7e5ef97ad5d9b7084fba932c91ab68
ToppCell	ILEUM-inflamed-(3)_MNP-(3)_moDC\|(3)_MNP / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	FRMD4A GNAS ZKSCAN1	7.20e-04	187	42	3	0099def970fbc828756fbf853eca2ce77b8cd342
ToppCell	3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MUC16 RNF223 MUC4	7.20e-04	187	42	3	71d99a1a95d3692a2891da49d4a243bae6e07fd0
ToppCell	wk_08-11-Epithelial-Proximal_epithelial-Proximal_secretory_2\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	MUC16 ATP13A4 MUC4	7.31e-04	188	42	3	07705bed928683470a52c8ccfa40ffb9a0971318
ToppCell	Fetal_29-31_weeks-Immune-interstitial_macrophage_(C1Q_positive)-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	FRMD4A ADGRE2 CD300C	7.31e-04	188	42	3	3be2d50148daa4eddddc2c7f269f45c97f7e4931
ToppCell	10x5'v1-week_17-19-Myeloid_macrophage-stroma-osteoclast\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	SIGLEC15 AHNAK2 CD276	7.31e-04	188	42	3	762b52f21d2bc5409f86746a904c4358490be9c0
ToppCell	10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8\|GI_small-bowel / Manually curated celltypes from each tissue	KMT2A KMT2C TASOR2	7.31e-04	188	42	3	ab9b725d6e0cdab8e9ddda6dee09e14730e9a578
ToppCell	5'-GW_trimst-2-SmallIntestine-Hematopoietic-T_cells-SELL+_CD8_T\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TCF7 HLA-C GYPC	7.31e-04	188	42	3	a2f42a86418a52cd12c3a699ab290d7d86826359
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_INF-D\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	SIGLEC15 GYPC CD300C	7.31e-04	188	42	3	e32d95f8e86111245d7f4b5fd72d2471fe0f1304
ToppCell	10x_3'_v3-spleen_(10x_3'_v3)\|10x_3'_v3 / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	PNRC1 ADGRE2 HLA-C	7.42e-04	189	42	3	0fe8901e10c619c93b7788792da1706a32102c6e
ToppCell	Severe_COVID-19-Epithelial-undefined_Epi\|Severe_COVID-19 / Disease group,lineage and cell class （2021.01.30）	MUC16 RNF223 MUC4	7.42e-04	189	42	3	8cbd35320c7e7ff013ef0c0f13f8d875db1c53cd
ToppCell	ILEUM-inflamed-(5)_Plasma-(5)_IgA_plasma_cells\|(5)_Plasma / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	KMT2A PNRC1 GNAS	7.42e-04	189	42	3	a0634d72bfdd5f93877724ed6480b50a3a046f71
ToppCell	saliva-Severe-critical_progression_d28-40-Myeloid-Monocytic-Nonclassical_Monocyte-Mono_c4-CD14-CD16\|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)	GYPC CD300C CD276	7.42e-04	189	42	3	0a490730cdc912d5233de59057550de0e4065747
ToppCell	systemic_lupus_erythematosus-treated-Lymphocytic_T-CytoT_GZMK+-female\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	TCF7 HLA-C GYPC	7.42e-04	189	42	3	f1129eb122bbc051457c5545f1a267beb988b0f2
ToppCell	systemic_lupus_erythematosus-treated-Lymphocytic_T-CytoT_GZMK+\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	TCF7 HLA-C GYPC	7.42e-04	189	42	3	0b012ee301419fa9ccc387c3ff66c2344b349a97
ToppCell	Ciliated_cells-A\|World / lung cells shred on cell class, cell subclass, sample id	MAP1A MUC4 FRMPD2	7.54e-04	190	42	3	cd87731aaa7d252424f79cfce9f7931457f17bdf
ToppCell	3'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Deuterosomal-Deuterosomal_L.0.3.4.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MUC16 MAP1A MUC4	7.54e-04	190	42	3	0adb24dafa077156bbc73a8d8cbf3d9eeb6e08df
ToppCell	3'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Deuterosomal\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MUC16 MAP1A MUC4	7.54e-04	190	42	3	05455775845f4ded5c27e7b83242078d23162aaf
ToppCell	severe_COVID-19-RBC\|severe_COVID-19 / disease group, cell group and cell class (v2)	FRMD4A E2F2 GYPC	7.54e-04	190	42	3	3a5723c2daf58c1932edd70910db4b8b30f63f42
ToppCell	BAL-Control-Epithelial-Epithelial\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	MUC16 MUC4 FRMPD2	7.65e-04	191	42	3	df8a1a6e78aa0cb941b94cb676bd6891d79f3687
ToppCell	10x5'v1-week_12-13-Myeloid_macrophage-stroma\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	SIGLEC15 AHNAK2 CD276	7.65e-04	191	42	3	4cebaf31d4f09f4ab273a819ad5cbff7d9a9b341
ToppCell	BAL-Control-Epithelial-Epithelial-Ciliated\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	MUC16 MUC4 FRMPD2	7.65e-04	191	42	3	7b5da29109aa28768c67653a1bc0f385c2d2269b
ToppCell	nucseq-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Ciliated\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	MUC16 MUC4 FRMPD2	7.65e-04	191	42	3	e417bf491f8b8d7838a61f7f4f6b1740ba97aa3f
ToppCell	BAL-Control-Epithelial\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	MUC16 MUC4 FRMPD2	7.65e-04	191	42	3	9f19098f260d5542aa8ba7eb6f91b44d0db6e0a4
ToppCell	356C-Epithelial_cells-Epithelial-F_(Ciliated)-\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	MAP1A MUC4 FRMPD2	7.65e-04	191	42	3	dad675251e129254955eac179c84a641a4864586
ToppCell	BAL-Control-Epithelial-Epithelial-Ciliated-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	MUC16 MUC4 FRMPD2	7.65e-04	191	42	3	fa9f8b50bfc7911c858bc2f9dcd204873d97ac61
ToppCell	10x5'v1-week_12-13-Myeloid_macrophage\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	SIGLEC15 AHNAK2 CD276	7.65e-04	191	42	3	be2fe2583bdcee0b35c43a347da9c4adb93e30e0
ToppCell	Control-Epithelial\|Control / Disease group,lineage and cell class （2021.01.30）	MUC16 MUC4 FRMPD2	7.65e-04	191	42	3	b78547dae8328244a47c83346447bdd787efbcae
ToppCell	nucseq-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	MUC16 MUC4 FRMPD2	7.65e-04	191	42	3	9d31c8424d35bdc0c27188b68bfd0f731af3600b
ToppCell	Control-Myeloid-Macrophage_Alveolar\|Myeloid / Disease state, Lineage and Cell class	STIM1 FRMD4A GYPC	7.65e-04	191	42	3	a7bb8aba9c59c037d995a77928cc7b4d5cbb82b9
ToppCell	356C-Epithelial_cells-Epithelial-F_(Ciliated)\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	MAP1A MUC4 FRMPD2	7.65e-04	191	42	3	6d2cf41ee946137c039ddcc13593fc3f670afbba
ToppCell	BAL-Control-Epithelial-Epithelial-Ciliated-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	MUC16 MUC4 FRMPD2	7.65e-04	191	42	3	b4e335e798c9617356b8e24412f9270c42dce656
Disease	Acute erythroleukemia - M6a subtype	NUP98 KMT2A	4.99e-05	8	40	2	C2930975
Disease	Acute myeloid leukemia FAB-M6	NUP98 KMT2A	4.99e-05	8	40	2	C2930976
Disease	Acute erythroleukemia - M6b subtype	NUP98 KMT2A	4.99e-05	8	40	2	C2930977
Disease	Acute erythroleukemia	NUP98 KMT2A	4.99e-05	8	40	2	C2930974
Disease	prostate cancer (is_marker_for)	KMT2A KMT2C TCF7 CDK13	5.92e-05	156	40	4	DOID:10283 (is_marker_for)
Disease	Liver Diseases, Parasitic	KMT2C GNAS	6.41e-05	9	40	2	C0023897
Disease	congenital heart disease (implicated_via_orthology)	USP36 KMT2A KMT2C	1.14e-04	69	40	3	DOID:1682 (implicated_via_orthology)
Disease	acute myeloid leukemia (implicated_via_orthology)	NUP98 KMT2A	1.17e-04	12	40	2	DOID:9119 (implicated_via_orthology)
Disease	pancreatic cancer (is_marker_for)	MUC16 GNAS MUC4	3.51e-04	101	40	3	DOID:1793 (is_marker_for)
Disease	COVID-19 (is_implicated_in)	HLA-C KIR3DS1	3.70e-04	21	40	2	DOID:0080600 (is_implicated_in)
Disease	Precursor B-cell lymphoblastic leukemia	KMT2A HLA-C	3.70e-04	21	40	2	C1292769
Disease	Intrahepatic Cholangiocarcinoma	KMT2C GNAS	4.85e-04	24	40	2	C0345905
Disease	malaria (is_implicated_in)	KIR3DS1 GYPC	4.85e-04	24	40	2	DOID:12365 (is_implicated_in)
Disease	Extrahepatic Cholangiocarcinoma	KMT2C GNAS	4.85e-04	24	40	2	C3805278
Disease	Cholangiocarcinoma	KMT2C GNAS	5.70e-04	26	40	2	C0206698
Disease	Acute Myeloid Leukemia, M1	NUP98 KMT2A KMT2C	6.54e-04	125	40	3	C0026998
Disease	Acute Myeloid Leukemia (AML-M2)	NUP98 KMT2A KMT2C	6.54e-04	125	40	3	C1879321
Disease	Burkitt Lymphoma	KMT2A HLA-C	1.10e-03	36	40	2	C0006413
Disease	duodenal ulcer	GNAS TTLL8	1.10e-03	36	40	2	EFO_0004607
Disease	human immunodeficiency virus infectious disease (is_implicated_in)	HLA-C KIR3DS1	1.29e-03	39	40	2	DOID:526 (is_implicated_in)

Protein segments in the cluster

Peptide	Gene	Start	Entry
GWPAATMTPAETSPT	GNAS	506	P84996
DMTFSTWTPPPGVHS	ADGRE2	261	Q9UHX3
PPPFTSSWHVMSVIF	CDCP2	111	Q5VXM1
DPSWPPLNQTSHSDM	ATP13A4	1161	Q4VNC1
TGQPMTFPPEALWVT	CD276	456	Q5ZPR3
SGPSLMHGQTWTSPA	CDK13	1471	Q14004
MGTSGPPTKLPVHTW	CD300C	146	Q08708
TMASWVTHPPQTSTP	MUC16	11686	Q8WXI7
PASGSPIQHWMVISE	MUC4	5221	Q99102
LMNIPSTSSWSVPPP	NUP98	1076	P52948
IFSDMGAWTLPSHPP	HAX1	91	O00165
SGHTSPVRMPSLPGW	KMT2C	3321	Q8NEZ4
IPMGSPTLWPETEAH	MAP1A	2131	P78559
STTATAELGWMVHPP	EPHB2	26	P29323
LSWEPSSQPTIPIMG	HLA-C	296	P10321
SVLPKPPSHWMGSTV	PNRC1	291	Q12796
SSPLSPNWMSPSDHQ	FAM205A	491	Q6ZU69
PMSNTTLPHTAWPLS	PRNT	41	Q86SH4
GLPHWNSQSSMPSTP	FRMD4A	661	Q9P2Q2
AMSPTELWPSGLSSP	E2F2	21	Q14209
QSSEWMPVSSHTPPG	LINC01599	291	Q8WXQ3
TWDSLSGPPVQSMHA	FRMPD2	741	Q68DX3
SSISDHTPWLMPPTI	KMT2A	576	Q03164
TTTIAEPDPGMSGWP	GYPC	31	P04921
LPSLPATGWTESMAP	DNER	136	Q8NFT8
SAIPGSPHPFSWSGM	RNF115	156	Q9Y4L5
SPHPFSWSGMLHSNP	RNF115	161	Q9Y4L5
VHSSPAQRWSMQVPP	SIGLEC15	36	Q6ZMC9
TWGHPSYLTPSPTMR	SERTAD4-AS1	141	Q5TG53
HSPTGWSAPSNPMVI	KIR3DS1	101	Q14943
HMLPQTVDWSSFPPQ	SPATA16	366	Q9BXB7
PSWQTAMHTPGPTEL	PRR12	116	Q9ULL5
IDPSWMGSTRPNPAH	STIM1	456	Q13586
HMVLPTWPGTPGSVS	AHNAK2	6	Q8IVF2
MAPHDPGSLTTLVPW	ATRAID	1	Q6UW56
MSSGQQVWHTAVPPP	RNF223	1	E7ERA6
GSLSSAQPHSWMLTP	SHF	36	Q7M4L6
AQPHSWMLTPSPLNS	SHF	41	Q7M4L6
PWLIEINSSPTMHPS	TTLL8	536	A6PVC2
PHQPMTPERQSPHTW	ZNF135	176	P52742
SMSLIPTSPQVPGEW	SAMD4B	236	Q5PRF9
SWFTHPSLMLGSGVP	TCF7	211	P36402
VPGMETSLPPGHWTA	TASOR2	1886	Q5VWN6
HMWGQDSTLQDTPPP	ZKSCAN1	36	P17029
PWTSGIISAPDQLMP	SLC5A12	306	Q1EHB4
PMKTSHPVVASTWPV	USP36	721	Q9P275